K M T Astvad1, R K Hare1, M C Arendrup2. 1. Unit of Mycology, Statens Serum Institut, Copenhagen, Denmark. 2. Unit of Mycology, Statens Serum Institut, Copenhagen, Denmark; Department of Clinical Microbiology, Rigshospitalet, Copenhagen, Denmark; Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark. Electronic address: maca@ssi.dk.
Abstract
OBJECTIVE: The in vitro activity of isavuconazole was determined for 1677 Candida and 958 Aspergillus isolates from 2012 to 2014 with voriconazole as comparator. METHODS: Aspergillus isolates were screened for resistance using azole-agar. Aspergillus isolates that screened positive and all Candida isolates underwent EUCAST broth microdilution testing. Isolates were categorized as wild-type (wt) or non-wt, adopting EUCAST epidemiological cut-off values (ECOFFs) (where available) or wt upper limits (wtULs; two two-fold dilutions above the MIC50). The CYP51A gene was sequenced for non-wt Aspergillus fumigatus isolates. Itraconazole and posaconazole MICs were determined for selected Aspergillus isolates with isavuconazole MIC ≥2 mg/L. RESULTS: Isavuconazole MIC50 (range) (mg/L) against Candida species were: Candida albicans: ≤0.03 (≤0.03 to >4), Candida dubliniensis: ≤0.03 (≤0.03), Candida glabrata: ≤0.03 (≤0.03-4), Candida krusei: 0.06 (≤0.03-0.5), Candida parapsilosis: ≤0.03 (≤0.03-0.06), Candida tropicalis: ≤0.03 (≤0.03 to >4), Saccharomyces cerevisiae (anamorph: Candida robusta): ≤0.03 (≤0.03-0.5). Non-wt isavuconazole/voriconazole MICs were found for C. albicans: 0.8/1.0%, C. dubliniensis: 0/1.8%, C. glabrata: 14.9/9.5%, C. krusei: 2.7/1.4%, C. parapsilosis: 1.7/1.8%, C. tropicalis: 14.3/19.1% and S. cerevisiae: 10.0/0%. Isavuconazole MIC50 (range) (mg/L) against Aspergillus species were: A. fumigatus: 1 (≤0.125 to >16), Aspergillus niger: 2 (1-8), Aspergillus terreus: 1 (0.25-8), Aspergillus flavus: 1 (0.5-2), Aspergillus nidulans: ≤0.125 (≤0.125-0.25). Non-wt isavuconazole/voriconazole MICs were found for 13.7/15.2% A. fumigatus, 4.9/0% A. niger and 48.2/22.2% A. terreus. CONCLUSION: Isavuconazole displayed broad in vitro activity, similar to that of voriconazole. Up to 15% of C. glabrata, C. tropicalis and A. fumigatus isolates were non-wt, reflecting increased resistance at a reference centre and technical issues. Significant CYP51A alterations were reliably detected applying the isavuconazole breakpoint.
OBJECTIVE: The in vitro activity of isavuconazole was determined for 1677 Candida and 958 Aspergillus isolates from 2012 to 2014 with voriconazole as comparator. METHODS:Aspergillus isolates were screened for resistance using azole-agar. Aspergillus isolates that screened positive and all Candida isolates underwent EUCAST broth microdilution testing. Isolates were categorized as wild-type (wt) or non-wt, adopting EUCAST epidemiological cut-off values (ECOFFs) (where available) or wt upper limits (wtULs; two two-fold dilutions above the MIC50). The CYP51A gene was sequenced for non-wt Aspergillus fumigatus isolates. Itraconazole and posaconazole MICs were determined for selected Aspergillus isolates with isavuconazole MIC ≥2 mg/L. RESULTS:Isavuconazole MIC50 (range) (mg/L) against Candida species were: Candida albicans: ≤0.03 (≤0.03 to >4), Candida dubliniensis: ≤0.03 (≤0.03), Candida glabrata: ≤0.03 (≤0.03-4), Candida krusei: 0.06 (≤0.03-0.5), Candida parapsilosis: ≤0.03 (≤0.03-0.06), Candida tropicalis: ≤0.03 (≤0.03 to >4), Saccharomyces cerevisiae (anamorph: Candida robusta): ≤0.03 (≤0.03-0.5). Non-wt isavuconazole/voriconazole MICs were found for C. albicans: 0.8/1.0%, C. dubliniensis: 0/1.8%, C. glabrata: 14.9/9.5%, C. krusei: 2.7/1.4%, C. parapsilosis: 1.7/1.8%, C. tropicalis: 14.3/19.1% and S. cerevisiae: 10.0/0%. Isavuconazole MIC50 (range) (mg/L) against Aspergillus species were: A. fumigatus: 1 (≤0.125 to >16), Aspergillus niger: 2 (1-8), Aspergillus terreus: 1 (0.25-8), Aspergillus flavus: 1 (0.5-2), Aspergillus nidulans: ≤0.125 (≤0.125-0.25). Non-wt isavuconazole/voriconazole MICs were found for 13.7/15.2% A. fumigatus, 4.9/0% A. niger and 48.2/22.2% A. terreus. CONCLUSION:Isavuconazole displayed broad in vitro activity, similar to that of voriconazole. Up to 15% of C. glabrata, C. tropicalis and A. fumigatus isolates were non-wt, reflecting increased resistance at a reference centre and technical issues. Significant CYP51A alterations were reliably detected applying the isavuconazole breakpoint.
Authors: Maria A Mendoza; Anthony Anderson; Michele I Morris; Lazaros Lekakis; Jacques Simkins; Clara E Prado; Octavio V Martinez; Krishna V Komanduri; Jose F Camargo Journal: Mycopathologia Date: 2020-01-10 Impact factor: 2.574
Authors: Monica Fung; Brian S Schwartz; Sarah B Doernberg; Charles Langelier; Mimi Lo; Larissa Graff; Marisela Tan; Aaron C Logan; Peter Chin-Hong; Jennifer M Babik Journal: Clin Infect Dis Date: 2018-09-14 Impact factor: 9.079
Authors: Olga Rivero-Menendez; Juan Carlos Soto-Debran; Narda Medina; Jose Lucio; Emilia Mellado; Ana Alastruey-Izquierdo Journal: Antimicrob Agents Chemother Date: 2019-08-23 Impact factor: 5.191
Authors: Michael A Pfaller; Paul R Rhomberg; Nathan P Wiederhold; Connie Gibas; Carmita Sanders; Hongxin Fan; James Mele; Laura L Kovanda; Mariana Castanheira Journal: Antimicrob Agents Chemother Date: 2018-09-24 Impact factor: 5.191
Authors: Tamara Zoran; Bettina Sartori; Laura Sappl; Maria Aigner; Ferran Sánchez-Reus; Antonio Rezusta; Anuradha Chowdhary; Saad J Taj-Aldeen; Maiken C Arendrup; Salvatore Oliveri; Dimitrios P Kontoyiannis; Ana Alastruey-Izquierdo; Katrien Lagrou; Giuliana Lo Cascio; Jacques F Meis; Walter Buzina; Claudio Farina; Miranda Drogari-Apiranthitou; Anna Grancini; Anna M Tortorano; Birgit Willinger; Axel Hamprecht; Elizabeth Johnson; Lena Klingspor; Valentina Arsic-Arsenijevic; Oliver A Cornely; Joseph Meletiadis; Wolfgang Prammer; Vivian Tullio; Jörg-Janne Vehreschild; Laura Trovato; Russell E Lewis; Esther Segal; Peter-Michael Rath; Petr Hamal; Manuel Rodriguez-Iglesias; Emmanuel Roilides; Sevtap Arikan-Akdagli; Arunaloke Chakrabarti; Arnaldo L Colombo; Mariana S Fernández; M Teresa Martin-Gomez; Hamid Badali; Georgios Petrikkos; Nikolai Klimko; Sebastian M Heimann; Omrum Uzun; Maryam Roudbary; Sonia de la Fuente; Jos Houbraken; Brigitte Risslegger; Cornelia Lass-Flörl; Michaela Lackner Journal: Front Microbiol Date: 2018-03-28 Impact factor: 5.640